Biopharma SHAKTI scheme announced for biologics

A ₹10,000-crore, five-year push to build a domestic ecosystem for biologics and biosimilars and turn India into a global biopharma innovation and manufacturing hub.

What happened

• The Government has announced the Biopharma SHAKTI scheme to strengthen the domestic biopharmaceutical sector and lift India's competitiveness in biologics and biosimilars.
• The scheme carries an outlay of ₹10,000 crore over five years and is steered by the Department of Pharmaceuticals (Ministry of Chemicals & Fertilizers).
• The stated objective is a globally competitive domestic ecosystem for biologics and biosimilars that supports affordable healthcare at home and lets India emerge as a global biopharma manufacturing and innovation hub.
• A flagship element is a nationally accredited network of 1,000 clinical-trial sites under the ICMR, expanding India's clinical-research footprint.
• The release was placed by the Minister of State for Health & Family Welfare, Smt. Anupriya Patel, in the Rajya Sabha. Notably, the contours of the scheme are still under deliberation — the architecture is announced, the fine print is being finalised.

Background & context

To read this scheme correctly, an aspirant needs the vocabulary first. Biologics are medicines made inside living cells — large, complex protein molecules such as monoclonal antibodies, vaccines, insulin and gene therapies — as opposed to the small chemical molecules that built India's generic-drug empire. Because a biologic cannot be copied atom-for-atom, a follow-on version made after the originator's patent expires is called a biosimilar (a "highly similar" copy), not a generic. India earned the title "pharmacy of the world" on cheap chemical generics; the next frontier — and the harder, higher-value one — is biologics, where global majors dominate and entry costs are steep.

Biopharma SHAKTI sits inside a wider arc of Indian self-reliance schemes in the drug sector. It is a sibling, in spirit, to the Production Linked Incentive (PLI) scheme for Bulk Drugs / KSMs (Key Starting Materials), Drug Intermediates and APIs and the PLI for Pharmaceuticals — both run by the same Department of Pharmaceuticals to cut import dependence (notably on China for active pharmaceutical ingredients). It also complements the Strengthening of Pharmaceutical Industry (SPI) scheme and the National Biopharma Mission (Innovate in India / i3), an earlier Department of Biotechnology–BIRAC programme that first seeded India's biosimilar and vaccine R&D capacity. Where i3 was an early, smaller catalytic push, Biopharma SHAKTI is positioned as the larger, full-stack industrial-and-regulatory build-out. The "SHAKTI" branding follows the government's habit of naming flagship missions with a resonant acronym; the body of the release does not spell the acronym out, so it is treated here as the scheme's name rather than expanded into a possibly-wrong full form.

The choice of administering chain matters. The scheme is anchored in the Department of Pharmaceuticals, but it deliberately pulls in two other arms of the State: the Indian Council of Medical Research (ICMR), India's apex biomedical research body under the Ministry of Health & Family Welfare, which will host the accredited clinical-trial network; and the Central Drugs Standard Control Organisation (CDSCO) — India's national drug regulator, headed by the Drugs Controller General of India (DCGI) — which is to be strengthened so that Indian approvals become globally credible. That tri-junction of industry policy, medical research and regulation is the scheme's defining design feature. The Department of Pharmaceuticals itself is one of the departments under the Ministry of Chemicals & Fertilizers, and is the same department that runs the production-linked incentive schemes for bulk drugs and pharmaceuticals — so a single nodal department now carries both the small-molecule (API) self-reliance agenda and the new large-molecule (biologics) agenda.

A word on where the money is meant to go versus how a generic-drug incentive works. A classic PLI rewards a firm after it produces and sells, on incremental output. Biopharma SHAKTI, by contrast, is deliberately front-loaded across the value chain — discovery grants and equity at the riskiest, pre-revenue stage; manufacturing incentives for the upstream fermentation inputs and for the finished biosimilars; capital for delivery devices and packaging; and non-monetary institution-building (NIPER network, R&D network, accredited trial sites, regulatory cadre). That spread is why the release lists seven distinct components rather than a single incentive formula: the scheme is trying to fix an entire missing ecosystem, not subsidise one factory line.

For Prelims

• Scheme: Biopharma SHAKTI · announced 2026 · for biologics & biosimilars.
• Outlay & period: ₹10,000 crore over five years.
• Nodal body: Department of Pharmaceuticals, under the Ministry of Chemicals & Fertilizers.
• Clinical-trial network: a nationally accredited 1,000-site clinical-trial network under ICMR.
• Regulator strengthened: CDSCO — via a dedicated Scientific Review Cadre and specialist positions for advanced fields such as gene therapy — to enable faster, globally credible drug approvals.
• Goal: affordable healthcare at home + India as a global biopharma manufacturing and innovation hub.
• Status: announced; contours under deliberation (architecture set, details being finalised).

The seven named components (the full set — built to survive a "how many of the following are components" question):

• 1. Biopharma Discovery Grant Fund + a Discovery & Development Equity Fund — early-stage research money plus risk equity.
• 2. Biopharma-focused NIPER Network + a National Biopharma R&D Network — building academic and institutional research capacity (NIPER = National Institute of Pharmaceutical Education and Research).
• 3. India Clinical Trial Sites Network — the 1,000 accredited sites under ICMR.
• 4. Fermentation-based Bulk Drugs & Building Blocks Manufacturing Incentive — domestic production of the upstream inputs that biologics need.
• 5. Biopharma Delivery Devices & Packaging Manufacturing Ecosystem — syringes, vials, cold-chain and delivery hardware.
• 6. Biosimilars & Emerging Biologics Manufacturing Initiative — the core production push.
• 7. Regulatory Strengthening for Global-best Drug Review Standards — the CDSCO upgrade.

What it is NOT: It is not a scheme for ordinary chemical (small-molecule) generic drugs — its target is the harder class of biologics and biosimilars. It is not the PLI for Bulk Drugs/APIs (a separate, earlier Department of Pharmaceuticals incentive) and not the older National Biopharma Mission / i3 run via BIRAC. The 1,000-site trial network sits under ICMR, not under CDSCO; CDSCO is the regulator being strengthened, not the trials host. And a biosimilar is not a generic — it is a "highly similar" follow-on biologic, never an identical copy.

Why it matters

India's pharmaceutical strength has historically been concentrated in low-cost chemical generics, where it supplies a large share of the world's medicines by volume. Biologics are a different game: they are costlier to develop, harder to manufacture, and tightly bound to advanced manufacturing (fermentation, cell-culture), specialised delivery devices and a credible regulatory regime. The problem Biopharma SHAKTI sets out to address is precisely this capability gap — India risks being a price-taker in the fastest-growing, highest-value segment of modern medicine if it cannot build domestic discovery, manufacturing and approval capacity for biologics.

Three structural problems are visible in the design. First, discovery and early-stage risk capital — addressed by the grant and equity funds, because biologic R&D is too long-horizon for ordinary credit. Second, a thin clinical-research base — addressed by the 1,000-site ICMR network, which both speeds Indian trials and makes Indian data globally usable. Third, a regulatory credibility deficit — addressed by the CDSCO upgrade, since a medicine is only exportable if the approving authority is trusted abroad; building a Scientific Review Cadre with gene-therapy expertise is an admission that the current regulator is under-resourced for frontier biology. The scheme's twin promise — affordable healthcare at home and a global biopharma hub abroad — is the classic Atmanirbhar (self-reliance) framing: substitute imports, then export.

The affordability angle deserves its own line because it is where the scheme touches ordinary patients. Biologics — cancer monoclonal antibodies, insulin analogues, autoimmune therapies — are among the most expensive medicines in the world, and their cost is a major driver of catastrophic health expenditure. A credible domestic biosimilar industry is the single largest lever to bring those prices down for Indian patients, exactly as Indian generics once collapsed the global price of antiretrovirals. So the scheme is simultaneously an industrial-policy instrument (build an export hub) and a public-health instrument (make high-end medicine affordable). For the exam, that dual character is what lets the same fact be deployed in a GS3 economy/technology answer and a GS2 health-policy answer.

A note of caution the aspirant should carry: because the contours are still under deliberation, the seven components, the ₹10,000-crore figure and the five-year horizon are the announced frame, not a finalised operational guideline. The component-wise allocation, the eligibility of firms, the mode of incentive (grant versus equity versus production-linked payout) and the timeline are yet to be notified. In an answer or a card, the safe formulation is "announced with an outlay of ₹10,000 crore over five years", not "₹10,000 crore sanctioned and disbursed".

For Mains

Source